Ilias Ettayebi
Overview
Explore the profile of Ilias Ettayebi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
734
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ishak C, Marhon S, Tchrakian N, Hodgson A, Loo Yau H, Gonzaga I, et al.
Cancer Discov
. 2025 Jan;
PMID: 39776167
Epigenetic therapies facilitate transcription of immunogenic repetitive elements that cull cancer cells through 'viral mimicry' responses. Paradoxically, cancer-initiating events also facilitate transcription of repetitive elements. Contributions of repetitive element transcription...
2.
Feng S, Marhon S, Sokolowski D, DCosta A, Soares F, Mehdipour P, et al.
Nat Commun
. 2024 Oct;
15(1):9321.
PMID: 39472584
Inactivating mutations in SMARCB1 confer an oncogenic dependency on EZH2 in atypical teratoid rhabdoid tumors (ATRTs), but the underlying mechanism has not been fully elucidated. We found that the sensitivity...
3.
Attie de Castro F, Mehdipour P, Chakravarthy A, Ettayebi I, Loo Yau H, Medina T, et al.
Br J Haematol
. 2023 Sep;
204(1):206-220.
PMID: 37726227
Progression to aggressive secondary acute myeloid leukaemia (sAML) poses a significant challenge in the management of myeloproliferative neoplasms (MPNs). Since the physiopathology of MPN is closely linked to the activation...
4.
Mehdipour P, Marhon S, Ettayebi I, Chakravarthy A, Hosseini A, Wang Y, et al.
Nature
. 2021 Mar;
591(7850):E20.
PMID: 33654322
No abstract available.
5.
Loo Yau H, Bell E, Ettayebi I, Campos de Almeida F, Boukhaled G, Shen S, et al.
Mol Cell
. 2021 Feb;
81(7):1469-1483.e8.
PMID: 33609448
We demonstrate that DNA hypomethylating agent (HMA) treatment can directly modulate the anti-tumor response and effector function of CD8 T cells. In vivo HMA treatment promotes CD8 T cell tumor...
6.
Mehdipour P, Marhon S, Ettayebi I, Chakravarthy A, Hosseini A, Wang Y, et al.
Nature
. 2020 Oct;
588(7836):169-173.
PMID: 33087935
Cancer therapies that target epigenetic repressors can mediate their effects by activating retroelements within the human genome. Retroelement transcripts can form double-stranded RNA (dsRNA) that activates the MDA5 pattern recognition...
7.
Taylor K, Loo Yau H, Chakravarthy A, Wang B, Shen S, Ettayebi I, et al.
J Immunother Cancer
. 2020 Aug;
8(2).
PMID: 32753546
Purpose: To evaluate whether administration of the oral DNA hypomethylating agent CC-486 enhances the poor response rate of immunologically 'cold' solid tumors to immune checkpoint inhibitor durvalumab. Experimental Design: PD-L1/PD-1...
8.
Deblois G, Madani Tonekaboni S, Grillo G, Martinez C, Kao Y, Tai F, et al.
Cancer Discov
. 2020 Jun;
10(9):1312-1329.
PMID: 32546577
Tumor progression upon treatment arises from preexisting resistant cancer cells and/or adaptation of persister cancer cells committing to an expansion phase. Here, we show that evasion from viral mimicry response...
9.
Ettayebi I, Loo Yau H, De Carvalho D
Methods Enzymol
. 2019 Nov;
629:35-51.
PMID: 31727248
Nucleic acid sensing is a central mechanism for innate immune defense against foreign molecules that culminates with an activation of interferon signaling pathways. This involves detection of molecular patterns associated...
10.
Shen S, Singhania R, Fehringer G, Chakravarthy A, Roehrl M, Chadwick D, et al.
Nature
. 2018 Nov;
563(7732):579-583.
PMID: 30429608
The use of liquid biopsies for cancer detection and management is rapidly gaining prominence. Current methods for the detection of circulating tumour DNA involve sequencing somatic mutations using cell-free DNA,...